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Electroporation-mediated PDGF receptor-IgG chimera gene
transfer ameliorates experimental glomerulonephritis
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Electroporation-mediated PDGF receptor-IgG chimera gene man glomerular diseases [1, 2]. Both processes are thought
transfer ameliorates experimental glomerulonephritis. to play an important role in the development of glomeru-
Background. Mesangial cell proliferation and phenotypic al- losclerosis and renal failure. Despite the diverse causesteration occur in an early phase of glomerular injury and pre-
of glomerular injury, the glomerular responses to eachcede increased extracellular matrix accumulation. A critical
type of injury show remarkable similarities. Recent stud-growth factor responsible for mesangial proliferation is plate-
let-derived growth factor (PDGF), which has proved to be a ies have suggested that mesangial cell proliferation and
potent mitogen. alteration of phenotype commonly occur in the early
Methods. We generated a chimeric cDNA encoding an ex- phase of glomerular injury and precede an increasedtracellular domain of the b-PDGF receptor fused with IgG-
ECM accumulation [3].Fc, termed PDGFR/Fc, and examined the feasibility of gene
A growing body of evidence suggests that platelet-therapy targeting PDGF using PDGFR/Fc.
Results. Chimeric PDGFR/Fc molecule completely inhib- derived growth factor (PDGF) is the most potent regu-
ited the tyrosine phosphorylation of b-PDGF receptors and lator of the mesangial growth and is associated with
cellular proliferation induced by PDGF in vitro. We then intro- glomerular matrix accumulation: (1) mesangial cellsduced the PDGFR/Fc expression vector into the muscle of
produce PDGF in vitro, and various growth factorsanti–Thy-1 model of glomerulonephritic rats by electropora-
induce mesangial cell proliferation via induction oftion. The plasma concentration of chimeric PDGFR/Fc levels
was 244.4 6 89.8 ng/mL four days after transfection. On day autocrine or paracrine PDGF-B excretion [4]; (2) the
5, PDGFR/Fc gene transfer significantly reduced the number PDGF-B chain and its receptor are overexpressed in
of PCNA-positive cells and glomerular cell numbers by 59.6 many glomerular diseases [5, 6]; (3) the infusion ofand 23.2%, respectively. Northern blot analysis demonstrated
PDGF-BB [7] or the glomerular transfection with athat glomerular mRNA levels of a-smooth muscle action, trans-
PDGF-B cDNA [8] can induce selective mesangial cellforming growth factor-b1, and type I collagen were also sup-
pressed on days 5 and 7 by the PDGFR/Fc transfection. There proliferation and matrix accumulation in vivo; (4)
was a significant reduction in the matrix score of the transfected PDGF-B [9] or b receptor [10] knockout mice fail to
nephritic rats (2.91 6 0.75 and 2.06 6 0.95; disease control develop a mesangium; and (5) inhibition of PDGF withgroup vs. treated group, P , 0.001).
a neutralizing antibody [11] or PDGF aptamer [12] leadsConclusion. These results suggest that gene therapy by the
to a significant reduction of both mesangial cell prolifera-manipulation of PDGF action using electroporation-mediated
PDGFR/Fc gene transfer to the skeletal muscle might be a tion and matrix accumulation in the anti–Thy-1 model
useful treatment for mesangioproliferative glomerulonephritis. of experimental glomerulonephritis.
Platelet-derived growth factor is a disulfide-bonded
dimeric glycoprotein that is composed of two highly ho-
The proliferation of glomerular mesangial cells and the mologous chains, known as A and B chains, which give
expansion of the mesangial extracellular matrix (ECM) rise to the formation of three different isoforms: AA, AB,
are central features of numerous experimental and hu- and BB. The activity of PDGF is mediated through its
interaction with a high-affinity cell surface receptor with
intrinsic tyrosine kinase activity. The two types of PDGFKey words: glomerular injury, mesangial cell, platelet-derived growth
factor, extracellular matrix, renal failure, skeletal muscle. receptors (a and b) have been cloned and sequenced
[13–17]. aa Receptors are able to interact with all PDGFReceived for publication August 25, 2000
isoforms. ab Receptors can bind with PDGF-AB andand in revised form December 26, 2000
Accepted for publication January 10, 2001 PDGF-BB, and bb-receptors can bind only PDGF-BB.
Studies using glomerulonephritic rats demonstrated thatÓ 2001 by the International Society of Nephrology
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b-PDGF receptor (bPDGFR) mRNA and protein are
up-regulated in association with the PDGF up-regulation
[5]. In contrast to the bPDGFR, no a-PDGF receptor
mRNA and protein could be identified in normal or
anti–Thy-1 glomerulonephritic rats [5]. Subsequent to
ligand binding, cellular events would occur: dimerization
of the receptors [18], receptor autophosphorylation [19],
and a ligand-dependent association of the receptor with
its cytoplasmic substrates, including the c-raf protein
[20], and GTPase-activating protein [21]. In this context,
targeting bPDGFR may be a feasible strategy for inhibi-
tion of PDGF BB-induced cellular events.
To create an inhibitor with the capacity to block the
binding of PDGF-BB to its high-affinity receptor and
thereby to prevent the subsequent signal transduction,
we have generated a chimeric inhibitor molecule, termed
PDGFR/Fc, in which the extracellular portion of the
bPDGFR was fused to an immunoglobulin heavy chain
Fc fragment (Fig. 1). When expressed in mammalian
cells, PDGFR/Fc is expected to be secreted as a disulfide-
linked homodimer. The design of this molecule was
based on previous findings demonstrating that similar
chimeric molecules possess functional binding sites and
a longer plasma half-life compared with the soluble ex-
tracellular domain [22]. A repeated injection of the puri-
fied recombinant PDGFR/Fc may be applicable for mo-
lecular intervention of PDGF action. However, the
harvest of a large amount of purified PDGFR/Fc is ex-
pensive and time consuming. In contrast, gene transfer
of PDGFR/Fc to the skeletal muscle is less expensive and
it may provide lasting delivery of PDGFR/Fc chimeric
molecule. Muscle is an attractive site for gene therapy
Fig. 1. Immunoglobulin heavy chain (IgGHc; A), human b–platelet-
because of its specific capacity to be transfected by DNA, derived growth factor receptor (bPDGFR; B), and platelet-derived
growth factor receptor fused with IgG-Fc (PDGFR/Fc) chimeric inhibi-as DNA persists in an episomal state for several months
tor molecule (C). Consequent to ligand binding, signals are transducedand the muscle is able to secrete proteins [23, 24]. Fur-
into target cells (B). In contrast, the PDGFR/Fc chimeric molecule can
thermore, skeletal muscle is easy to approach and its bind to PDGF ligand and thereby block the signal transduction of
PDGF-BB (C). PDGFR cDNA encoding extracellular domain wasvolume is sufficiently large to inject DNA solution.
recombined in frame with the Fc portion of the human IgGFc at theElectroporation has been widely used to introduce
hinge region. The BamH I restriction site is underlined (D). Abbrevia-
foreign genes into cultured cells [25, 26]. Its advantages, tions are: VH, variable region; CH, constant region; H, hinge region;
EC, extracellular domain of bPDGFR; TK, tyrosine kinase domain;compared with viral vectors, are that it is a simple and
and TM, transmembrane domain.inexpensive methodology with a low intrinsic toxicity
[27]. Recently, gene transfer by electroporation in vivo
has been demonstrated to be effective for introducing
DNA into mouse muscle [28], mouse skin [29], chick whether in vivo electroporation-mediated PDGFR/Fc gene
embryos [30], rat liver [31], and murine melanoma [32]. transfer can produce significant amounts of PDGFR/Fc
Interleukin-5 gene transfer by the electroporation into molecule, and whether PDGFR/Fc chimeric gene trans-
skeletal muscle resulted in a significant increase in the fer can inhibit the early cellular events and ameliorate
protein level in blood of more than 100-fold compared the late ECM accumulation in rat anti-Thy-1 model of
with simple DNA injection [28]. In addition, regenerat- mesangioproliferative glomerulonephritis.
ing muscle by treatment with bupivacaine prior to the
transfection produced an 80-fold or more increased gene
METHODSexpression at the protein level [33].
Cell linesOur study examined the possibility of using gene ther-
apy to determine whether the PDGFR/Fc chimeric mole- Human mesangial cells were purchased from Clonetics
(Walkersville, MD, USA) and were maintained in mes-cule can block the signal transduction of PDGF in vitro,
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angial cell basal medium (MsBM; Clonetics) supple- constructed by cloning the luciferase gene at HindIII
and BamHI sites of pAct-CAT [37].mented with 5% fetal calf serum (FCS), 50 mg/mL of
gentamicin, and 50 ng/mL of amphotericin-B. NIH3T3
Detection of tyrosine phosphorylation ofcells were maintained in Dulbecco’s modified Eagle’s
b-PDGF receptormedium (DMEM; GIBCO Laboratories, Grand Island,
NY, USA) containing 10% FCS, 100 U/mL of penicillin, The tyrosine phosphorylation of bPDGFR was as-
sayed by immunoblotting with the prior immunoprecipi-and 100 mg/mL of streptomycin. These cell lines were
used to examine the inhibitory effect of PDGFR/Fc on tation of bPDGFR. Confluent human mesangial cells in
a 75 cm2 flask were made quiescent by placing them inPDGF-b receptor phosphorylation and colony forming.
Rat mesangial cells were isolated and cultured as de- MsBM with 0.1% bovine serum albumin (BSA) for 18
hours. They were then treated with PDGF-BB (10 ng/mL;scribed previously [34].
Genzyme, Cambridge, MA, USA) and/or PDGFR/Fc
Construction of chimeric gene and purification of (10 mg/mL) for 10 minutes. Human mesangial cells were
chimeric protein then washed once with phosphate-buffered saline (PBS)
and scraped and pipetted into pestle-eppendorf tubes.The cDNA fragment corresponding to the extracellu-
lar domain of human bPDGFR gene (codons 183-1779) The pellet was lyzed with modified lysis buffer [1% Tri-
ton X-100, 50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L[13] was generated by reverse transcription-polymerase
chain reaction (RT-PCR) amplification from mRNA of NaCl, 2 mmol/L Na3VPO4, 5 mmol/L ethylenediamine-
tetraacetic acid (EDTA), 2 mg/mL aprotinin, 0.7 mg/mLthe human fibroblast cell line MRC5. The primers used
were as follows: 59-CCTCGAGCACCATGCGGCTTC pepstatin, 0.1 mg/mL Pefabloc SC, and 100 mmol/L
NaF]. After centrifugation of the cells for 20 minutes,CGGGTGCGATG and 59-CTCGGGATCCTTAAAG
GGCAAGGAGTGTGGCAC as sense and antisense the supernatants were transferred to fresh eppendorf
tubes. Supernatants pretreated by incubation with Bio-primers, respectively. For cutting out cDNA for the
bPDGFR, Xho I and BamH I restriction sites were added Mag anti-rabbit IgG agarose beads (PerSeptive Biosys-
tems, Framingham, MA, USA) were immunoprecipitatedto the sense and antisense primers, respectively, as indi-
cated by the underlines. The cycling parameters were one with rabbit anti-human bPDGFR antibody (Upstate Bio-
technology Inc., Lake Placid, NY, USA)-conjugated Bio-minute at 948C, two minutes at 628C, and three minutes
at 728C. The amplification was performed for 35 cycles Mag anti-rabbit IgG agarose beads for one hour at 48C.
Immune complex-conjugated beads were washed fiveby a GeneAmp PCR system 2400 (Perkin Elmer Cetus,
Norwalk, CT, USA). The fragment was cloned into the times with solubilization buffer (50 mmol/L Tris-HCl,
pH 7.5, 0.5% NP40, 150 mmol/L NaCl, 5 mmol/L EDTA,Sma I site of pUC 19. The amplified PCR product was
digested by Xho I and Bam H I and was inserted into 2 mmol/L Na3VO4). Immunoprecipitated bPDGFR mol-
ecule was separated by electrophoresis through 8% so-CD4Rg (a kind gift of Dr. Brian Seed, Behringwerke,
Germany) from which the Xho I–Bam H I fragment dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). They were then electrotransferred ontocontaining the CD4 gene was removed, thereby making
a fusion gene between the N-terminal half of bPDGFR nitrocellulose. Tyrosine phosphorylated proteins were
detected with antiphosphotyrosine antibody (4G10; Up-and the C-terminal half of human IgG1-Fc. pCAGGS-
PDGFR/Fc and pCAGGS-CD4/Fc were constructed by state Biotechnology Inc.) conjugated to horseradish per-
oxidase and visualized using an enhanced chemilumines-inserting the Xho I-Xma III fragment containing fusion
genes, PDGFR/Fc and the CD4/Fc genes, respectively, cence kit (Amersham Corp., Buckinghamshire, UK) as
previously described [38].into the Xho I site of pUC-CAGGS [35], which contains
the cytomegalovirus enhancer and the chicken b-actin
Assay for colony-forming assaypromoter.
These constructs (pCAGGS-PDGFR/Fc and pCAGGS- To quantitate the change in the cell proliferation of
NIH3T3 cells, we examined colony-forming efficiencyCD4/Fc) were transiently transfected into COS-1 cells
by the DEAE dextran method [36], and the cells were under PDGF-BB. NIH3T3 cells were seeded at a density
of 1000 cells per 35 mm dish in 1 mL of culture mediumthen cultured for four weeks in DMEM/F12 medium
(GIBCO Laboratories) containing 1% Nutridoma-NS containing DMEM, 0.8% methylcellulose (Shinetsu Chem-
ical Co., Tokyo, Japan), 1% deionized BSA (Organo(Boehringer Mannheim, Mannheim, Germany); the chi-
meric proteins (PDGFR/Fc and CD4/Fc) in the culture Teknika, Boxtel, Holland), 1.5% FCS, and 50 mmol/L
2-mercaptoethanol (Sigma Chemical Co., St. Louis, MO,supernatant were purified using Prosep-A (Bioprocess-
ing, Princeton, NJ, USA). These purified chimeric pro- USA) by the addition of PDGF-BB (30 ng/mL) with or
without PDGFR/Fc (10 mg/mL). To determine whetherteins were used for the in vitro study.
Luciferase gene was isolated from pGL2 promotor the addition of the chimeric molecule would inhibit the
cell proliferation, colonies were allowed to grow for twovector (Promega, Madison, WI, USA), and pActLuc was
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weeks of incubation. At this point, the number of colo- Electric pulse delivery and electrodes
nies with a diameter larger than 50 mm was counted. Electric pulses were delivered using an electric pulse
generator (Electro square Porator T820; BTX, San Diego,Effect of PDGFR/Fc on mesangial cell proliferation
CA, USA) connected with switch box (MBX-4BTX) and
Rat mesangial cells were seeded into 96-well culture monitored using a graphic pulse analyzer (Optimizer
plates at 2 3 104 cells per well and were cultured in 500; BTX). The shape of the pulse was a square wave, and
RPMI with 20% FCS. Twelve hours after seeding, cells the voltage remained constant during the pulse duration.
were growth arrested by culture in medium supple- Electrodes consisted of a pair of stainless tweezers type
mented with 0.4% FCS for 72 hours. Then the quiescent of instrument. Three pulses of the indicated voltage fol-
mesangial cells were stimulated for 24 hours with rat lowed by three more pulses of the opposite polarity were
PDGF-BB (10 ng/mL) with or without PDGFR/Fc (100 administrated to each injection site. Intrapulse delay was
ng/mL) or CD4/Fc (100 ng/mL), and were pulsed for the one second, and the duration of the pulse was fixed at
final eight hours with 1 mCi/mL [methyl-3H]-thymidine 50 msec.
(Amersham). After mitogenic stimulation, mesangial
cells were washed twice with PBS and harvested onto Experimental design
filter paper using an automated cell harvester (Wallac, For the in vivo study, pCAGGS-PDGFR/Fc was trans-
Turku, Finland). Incorporated radioactivities were mea- fected into the pretibial muscle of rats by the electropora-
sured by a scintillation counter (Wallac). tion-mediated gene transfer method using a tweezers
type of electrode and bupivacaine pretreatment. An acuteGene transfer into skeletal muscle by electroporation
anti–Thy-1 model of experimental glomerulonephritis
To examine the efficiency of gene transfer by the elec- was induced in six-week-old male Sprague-Dawley rats
troporation in vivo, we first transfected the luciferase by an intravenous injection of anti–Thy-1 antibody, OX-7
expression vector, pAct-Luc, to the muscle with or with- (1.5 mg/kg, a gift from Dr. Kenichi Isobe and Dr. Seiichi
out pretreatment of bupivacaine, which has been re- Matsuo, Nagoya University, Japan; termed day 0). Four
ported to induce muscle regeneration and enhance the
days before the OX-7 injection, 100 mL of 0.5% bupiva-
efficiency of gene transfer by intramuscular DNA injec-
caine were injected into the muscle. One day before the
tion [33]. Six-week-old male Sprague-Dawley rats (Japan
OX-7 injection, one group of six rats was anesthetized bySLC, Inc., Hamamatsu, Japan) were anesthetized by an
an intraperitoneal injection of pentobarbital (50 mg/kg),intraperitoneal injection of pentobarbital (50 mg/kg),
and bilateral pretibial muscles were exposed. One hun-and bilateral pretibial muscles were exposed. We in-
dred microliters of BSS containing 200 mg of pCAGGS-jected 200 mL of saline or 50, 100, or 200 mL of 0.5%
PDGFR/Fc (treated group) or saline (disease controlbupivacaine into the pretibial muscle three days before
group) were then injected into the bupivacaine-treatedpAct-Luc transfection (N 5 4 in each group). One hun-
muscles and 100 V electric pulses were delivered sixdred microliters of balanced salt solution (BSS) con-
times by the tweezers type of electrode. On days 5 andtaining 200 mg of luciferase expression vector was in-
7, the kidneys were perfused with cold autoclaved PBSjected into a bupivacaine-treated muscle with a 30-gauge
and were removed. Tissues for light microscopic exami-needle, and electric pulses were immediately delivered
nation were fixed with 4% paraformaldehyde overnightas described later in this article.
and dehydrated through a graded ethanol series and em-The reporter luciferase gene expression levels were
bedded in paraffin. Tissues for immunohistochemistrydetermined four days after transfection as reported by
were fixed in methyl Carnoy’s solution. For glomerularWolff et al with minor modification [39]. Pretibial mus-
RNA preparations, glomeruli were isolated from the re-cles were taken from the transfected rats under anesthe-
maining renal tissue by a standard sieving method [41, 42].sia. Transfected tissues were minced and homogenized in
1 mL of 1 3 cell lysis reagent (Promega) and centrifuged.
Detection of chimeric gene expressionThe supernatant of the lysate was examined for lucifer-
To examine the expression of chimeric PDGFR/Fc genease activity using the Promega Luciferase Assay System
transfected into muscle by electroporation, the plasmaand a Lumat LB 9501 luminophotometer (EG&G
concentration of secreted chimeric PDGFR/Fc was as-BERTHOLD, Wildbad, German). Luciferase activity of
sessed. Plasma samples were obtained from PDGFR/Fctransfected muscle was corrected based on the protein
gene-transfected or saline-treated rats four days afterconcentration, which was determined by the Bio-Rad
chimeric PDGFR/Fc gene transfection. Plasma levels ofprotein assay system (Bio-Rad, Hercules, CA, USA)
chimeric PDGFR/Fc were determined by enzyme-linked[40]. The data were expressed by dividing the corrected
immunosorbent assay (ELISA), using a monoclonal anti-luciferase activity (luciferase/protein concentration) for
body to human PDGF receptor (R&D Systems, Minne-each individual transfected muscle. The experiments
were repeated at least three times. apolis, MN, USA).
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Immunohistochemistry Histochemical analysis
To quantitate the total cell number per glomerulusImmunohistochemistry staining was performed on tis-
sues fixed in methyl Carnoy’s solution. Tissue sections and glomerular matrix accumulation, histologic sections
(2 mm) of the kidneys were stained with periodic acid-were preincubated with goat or horse serum diluted 1:20
with PBS for 30 minutes to block the nonspecific staining Schiff (PAS) reagent. All sections were evaluated by an
observer unaware of the experimental protocol. Thirtyand were then incubated with the primary antibodies
for 60 minutes at room temperature. Glomerular cell glomeruli were selected at random in cross-sections from
each rat. Glomerular hypercellularity was determinedproliferation was assessed by staining with 19A2 (Coulter
Corp., Hialeah, FL, USA), a mouse monoclonal IgM anti- by counting the cell number in 30 glomerular tuft sections
per animal. The degree of mesangial matrix accumula-body to the proliferative cell nuclear antigen (PCNA).
To stain a-smooth muscle actin (a-SMA), mouse IgG tion was determined as the percentage of each glomeru-
lus occupied by mesangial matrix, as described pre-anti–a-SMA monoclonal antibodies were used (Immu-
notech S.A., Cedex, Marseilles, France). After labeling, viously [41, 42].
the endogenous peroxidase activity in tissue sections was
Statistical analysisblocked by incubating in methanol with 0.3% hydroxyox-
idase for 30 minutes. Sections were then processed using All values are expressed as means 6 SD. Statistical
significance (defined as P , 0.01) was evaluated usingan avidin-biotinylated peroxidase complex method (Vec-
tastain ABC kit; Vector Laboratories, Inc., Burlingame, one-way analysis of variance (ANOVA).
CA, USA) with diaminobenzidine as the chromogen.
The sections were counterstained with methyl green.
RESULTS
Sections labeled with PCNA monoclonal antibodies
Effect of PDGFR/Fc chimera on tyrosinewere scored PCNA-positive cells within the glomerulus.
phosphorylation of bPDGFRCounting was performed under high-power (3400) mi-
croscopy. The number of PCNA-positive cells per glo- Receptor autophosphorylation on tyrosine residues is
an early event in signal transduction by PDGF receptormerulus was determined by the observation of randomly
selected 30 glomeruli for each animal. All scoring was following ligand binding. Since the PDGFR/Fc chimeric
molecule would be expected to inhibit the binding ofperformed on blinded slides.
PDGF-BB to bPDGFR on human mesangial cells, we
Glomerular RNA preparation and Northern examined whether the addition of the PDGFR/Fc chime-
blot analysis ric molecule would result in a specific block of PDGF-BB–
induced receptor autophosphorylation. Human mesan-To examine the effect on the level of a-SMA, trans-
gial cells were stimulated with PDGF-BB (10 ng/mL) informing growth factor-b1 (TGF-b1), and type I collagen
the presence or absence of 10 mg/mL of PDGFR/FcmRNA, Northern blot analysis was performed with glo-
chimeric molecule, and then bPDGFR was immunopre-merular RNA extracted from untransfected or trans-
cipitated from the mesangial cell lysate. The tyrosinefected nephritic rats. On days 5 and 7, total RNA was
phosphorylation of the bPDGFR was assessed by immu-prepared from glomeruli that were isolated by the graded
noblotting using the antiphosphotyrosine antibody 4G10.sieving technique as described previously [41, 42]. For
We found that PDGF-BB stimulated a 12-fold increasethe Northern blot analysis, 20 mg aliquots of total RNA
in tyrosine phosphorylation of bPDGFR. However, ad-were separated on 1% agarose formaldehyde gels and
ditional treatment with PDGFR/Fc chimeric moleculetransferred onto a nylon membrane (Hybonde-N; Amer-
completely blocked PDGF-stimulated tyrosine phosphor-sham). a-SMA cDNA was labeled by the random prim-
ylation (Fig. 2). The PDGFR/Fc chimeric molecule aloneing method using [g-32P] ATP and TGF-b1, type I colla-
did not affect the basal autophosphorylation activity.gen, and GAPDH cDNA were labeled using [a-32P] dCTP
Thus, the PDGFR/Fc chimeric molecule displayed the(3000 Ci/mmol; Amersham) [41, 42]. Hybridization was
expected inhibition for signal transduction of PDGF-BB.carried out at 428C overnight in 50% formamide, 10 3
Denhardt’s solution, 1% SDS, 5 3 standard saline citrate
Effect of chimeric molecule on cell proliferation(SSC), 50 mmol/L sodium phosphate, and 200 mg/mL
salmon sperm DNA. The blots for a-SMA were washed Platelet-derived growth factor-BB is known to be a
mesangial cell growth factor in the physiological or patho-two times at 508C and 558C in 5 3 SSC and 0.1% SDS
and two times at 558C in 1 3 SSC and 0.1% SDS. The physiological setting. Since the PDGFR/Fc chimeric mol-
ecule blocked the signal transduction of PDGF-BB, theblots for TGF-b1 and type I collagen were washed two
times at 508C and 558C in 1 3 SSC and 0.1% SDS and effects of the PDGFR/Fc chimeric molecule on cell pro-
liferation were examined. We employed a colony-form-two times at 508C and 558C in 0.1 3 SSC and 0.1% SDS.
The signals were quantitated by laser densitometry (Scan- ing efficiency assay as a quantitative measure of the cell
growth of NIH3T3 cells under PDGF-BB. The results wereningImager; Molecular Dynamics, Sunnyvale, CA, USA).
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Fig. 2. Effect of PDGFR/Fc chimera on tyrosine phosphorylation of
bPDGFR. The level of tyrosine phosphorylation of the bPDGFR was
determined in human mesangial cells. Cells were incubated with PDGF-
BB (10 ng/mL) with or without the PDGFR/Fc chimeric molecule
(10 mg/mL) for 10 minutes. Cells were solubilized, and bPDGFR was
isolated by immunoprecipitation with anti-human bPDGFR antibody-
conjugated immunobeads. Immunobead complexes were extensively
washed, separated on SDS-PAGE, and transferred to nitrocellulose
membranes. The level of phosphotyrosine within bPDGFR was deter-
mined by immunoblot analysis with antiphosphotyrosine antibody.
expressed as the number of colonies with a diameter larger
than 50 mm in the presence of PDGF-BB (30 ng/mL)
and/or PDGFR/Fc (10 mg/mL). PDGF-BB markedly in-
creased the colony numbers, while the addition of
Fig. 3. Effect of chimeric molecule on cell proliferation. (A) The effect
PDGFR/Fc chimeric molecule (10 mg/mL) to the PDGF- of the chimeric PDGFR/Fc molecule on PDGF-BB-induced cell prolif-
eration was evaluated by colony-forming efficiency assay. NIH3T3 cellssupplemented medium completely abolished the prolif-
were seeded at a density of 1000 cells per 35 mm dish and stimulatederating effects of PDGF-BB (Fig. 3A). The PDGFR/Fc
with PDGF-BB (30 ng/mL) and/or PDGFR/Fc (10 mg/mL). Two weeks
chimeric molecule alone did not alter the basal cell prolif- later, the number of colonies with a diameter of larger than 50 mm was
counted. (B) The effect of the chimeric PDGFR/Fc molecule on PDGF-eration activity. These results suggest that the effect of
BB–induced thymidine incorporation was evaluated. Rat mesangialthe chimeric molecule on the colony-forming efficiency
cells were growth arrested with 0.4% FCS for 72 hours and stimulated
is not due to the nonspecific toxicity of the chimeric by PDGF-BB (10 ng/mL) with PDGFR/Fc (100 ng/mL) or CD4/Fc (100
ng/mL) for 24 hours. [3H]-thymidine incorporation was determined inmolecule, but rather to the specific blockade of PDGF
final eight hours of stimulation. The values are expressed as mean 6signal transduction. In addition, the effect of chimeric
SD (N 5 4) and are representative of two independent experiments.
PDGFR/Fc on cell proliferation was examined using *P , 0.001 vs. the other groups.
3H-thymidine incorporation in rat mesangial cells. Twenty-
four hours after mitogenic stimulation of growth-arrested
gene expression of the transfected muscle (4.3 3 106,mesangial cells, 3H-thymidine incorporation was eight-
1.2 3 107, and 1.0 3 107 RLU/mg protein in 0.25, 0.5,fold increased in mesangial cells treated with PDGF-BB
and 1.0 mg bupivacaine-treated muscle) compared with
(10 ng/mL) over untreated mesangial cells. Additional the saline-treated muscle (3.5 3 105 RLU/mg protein).
treatment of PDGFR/Fc (100 ng/mL) completely blocked To show the feasibility of systemic delivery of
the increment of 3H-thymidine incorporation induced PDGFR/Fc chimeric molecule by transfecting into muscle,
by PDGF-BB, while the treatment with CD4/Fc (100 we examined the plasma concentration of secreted chime-
ng/mL) had no effect on 3H-thymidine incorporation in- ric PDGFR/Fc. Using antibody to human bPDGFR, we
duced by PDGF-BB (Fig. 3B). assessed the plasma levels of PDGFR/Fc by ELISA. On
day 4, plasma levels of chimeric protein were 244.4 6Effect of the gene transfer by the
89.8 ng/mL in the PDGFR/Fc gene-transfected groupelectroporation in vivo
and were undetectable in the saline-treated group.
To quantitate the efficiency of gene transfer by the elec-
Effects of chimeric gene transfer on cell proliferationtroporation in vivo, we first assessed the effect of bupiva-
of mesangial cells and glomerular extracellularcaine pretreatment on the efficiency of gene transfer by
matrix accumulationthe electroporation. The saline or bupivacaine-treated
muscles were electroporated with pActLuc. Pretreat- PDGFR/Fc chimeric gene transfection did not inter-
fere with the initial injury in the anti–Thy-1 model be-ment of bupivacaine significantly enhanced the luciferase
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Fig. 5. Representative photomicrographs of glomeruli stained for PAS
Fig. 4. Effect of chimeric gene transfer on glomerular cell proliferation. on day 7 in normal rats (A), untreated nephritic rats (B), and PDGFR/Fc
Representative immunohistochemical photomicrographs of glomeruli gene-transfected nephritic rats (C).
stained for PCNA on day 5 in normal rats (A), untreated nephritic rats
(B), and PDGFR/Fc gene-transfected nephritic rats (C).
cause both the untreated and PDGFR/Fc-treated rats (Figs. 4–6). The number of PCNA-positive cells per glo-
merulus was 0.35 6 0.61 in normal control rats. On dayhad equivalent mesangiolysis. The glomerular cell prolif-
eration assessed by PCNA expression in this Thy-1 model 5, the number of PCNA-positive cells per glomerulus
was significantly increased in untreated disease controlof glomerulonephritis has been demonstrated to be associ-
ated with the glomerular PDGF and bPDGFR expression group, whereas a significant reduction was observed in
treated group (4.7 6 2.4 and 1.9 6 1.6; PCNA-positive[11]. We examined whether PDGFR/Fc gene transfer
could decrease the glomerular cell proliferation assessed cells per glomerulus in disease control group and the
treated group, respectively, P , 0.001; Figs. 4 and 6A).by the PCNA expression and the glomerular cell number
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On days 5 and 7, the glomerular cell number was
significantly increased in the disease control nephritic
rats compared with normal control rats, and the peak
phase of cell proliferation was observed on day 7. Treat-
ment with PDGFR/Fc gene transfection reduced glomer-
ular hypercellularity by 23.2% on day 7 (P , 0.001),
and this reduction in the glomerular cell number was
associated with a significant reduction in PCNA-positive
cells (Figs. 5 and 6B).
In the kidneys from untreated nephritic rats, the glo-
meruli exhibited marked increases in the mesangial ECM
on day 7 (Fig. 5B). In contrast, the chimeric gene trans-
fection significantly suppressed the increase in mesangial
matrix expansion (Fig. 5C). The glomerular ECM expan-
sion was evaluated by a semiquantitative scoring of PAS-
positive area of tissue sections (Fig. 7). Compared with
the normal glomeruli, there was a marked increase in
the ECM deposition on day 7 in the untreated nephritic
rats (2.91 6 0.75). Treatment with PDGFR/Fc resulted
in a significant reduction in the glomerular matrix score
(2.06 6 0.95, P , 0.001 vs. disease control group). These
data demonstrated that chimeric PDGFR/Fc gene transfer
by electroporation suppressed glomerular ECM expansion.
Effects of chimeric gene transfer on phenotypic
changes of mesangial cells
To examine the effect of PDGFR/Fc gene transfection
on the phenotypic changes of mesangial cells, the sec-
tions were stained with a-SMA.
Fig. 6. Quantitative analysis of the effect on glomerular cell prolifera- An increased glomerular a-SMA expression was ob-
tion. The number of PCNA-positive cells per glomerulus (A) and the served on day 5 of untreated anti–Thy-1 nephritic rats
total cell number (B) in normal rats ( ), untreated nephritic rats
(Fig. 8B). In contrast, the treatment with the PDGFR/Fc(j), and PDGFR gene-transfected nephritic rats (h). The values are
expressed as mean 6 SD. *P , 0.001 vs. the other groups. Each group chimeric gene transfer inhibited the a-SMA expression
contained six animals. (Fig. 8C). We obtained glomerular RNA to examine
whether chimeric gene transfection could manipulate the
message of a-SMA in glomeruli. Glomeruli were isolated
by the graded sieving technique, and Northern blot anal-
ysis was performed to compare the levels of a-SMA
mRNA. On days 5 and 7, the mRNA levels of a-SMA
were elevated in disease control nephritic rats, whereas
PDGFR/Fc gene transfer reduced the level of a-SMA
mRNA compared with disease control group (Fig. 9).
These data were compatible with glomerular a-SMA
expression assessed by immunohistochemistry, as de-
scribed previously in this article.
Effects of chimeric gene transfer on gene expression
regarding glomerular matrix accumulation
It has been reported that PDGF induces mesangial
cells to express TGF-b [11], and TGF-b, in turn, induces
mesangial cells to produce a variety of ECM componentsFig. 7. Semiquantitation of the pathological effects of chimeric
PDGFR/Fc gene transfection. On day 7, the severity of the glomerular [43]. We then examined whether PDGFR/Fc gene trans-
damage of untreated nephritic rats (j) and nephritic rats with fer could manipulate the glomerular matrix accumula-
PDGFR/Fc gene transfection (h) was evaluated by ECM accumulation.
tion. On days 5 and 7, TGF-b1 and type I collagenThe values are expressed as mean 6 SD. *P , 0.001 vs. the other
groups. Each group contained six animals. mRNA levels were elevated in untreated disease control
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Fig. 9. Northern blot analysis of glomerular a-SMA, TGF-b1, and type
I collagen mRNA in nephritic rats treated with PDGFR/Fc transfection.
The glomeruli were obtained from age-matched normal control rats
(lane 1), nephritic rats treated with PDGFR/Fc gene transfer (lane 2),
and untreated nephritic rats (lane 3).
the disease progression in anti-Thy1 nephritis. Following
the reports of the T-cell receptor and CD4 immunoadh-
erin fusion proteins [22], receptor-IgG chimeras have been
used for structural and functional studies of the immuno-
globulin-like superfamily of receptors [44]. Therefore,
we also ligated the variable and CH1 domains from the
heavy chain with the extracellular domain (D1-5) of the
bPDGFR to the random structure of the hinge to facili-
tate dimer secretion and to allow maximal adaptability
to the ligand of PDGF-BB. In fact, our data confirmed
that the recombinant chimeric PDGFR/Fc molecule was
a competitive antagonist of PDGF-BB in three ways. The
recombinant chimeric PDGFR/Fc (1) completely blocked
the PDGF-BB–induced receptor autophosphorylation in
human mesangial cells, (2) diminished the PDGF-BB–
induced cell proliferation in cultured NIH3T3 cells, and
(3) inhibited the PDGF-BB–induced increase of 3H-thy-
midine incorporation.Fig. 8. Effect of chimeric gene transfer on phenotypic alteration. Rep-
The chimeric soluble PDGFR/Fc is a secreted protein,resentative immunohistochemical photomicrographs of glomeruli stained
for a-smooth muscle actin on day 5 in normal rats (A), untreated ne- and we observed increased plasma concentration of solu-
phritic rats (B), and PDGFR/Fc gene-transfected nephritic rats (C).
ble PDGFR/Fc molecule after transferring chimeric gene
into muscle. Here, electroporation-mediated gene trans-
fer into muscle was employed, and plasma levels of chi-
meric protein were over 200 ng/mL. The chimeric-solu-nephritic rats. On the other hand, the TGF-b1 and type
ble receptor with IgG-Fc was also reported to have anI collagen mRNA expressions in the glomeruli from ne-
advantage in in vivo studies because of its extendedphritic rats treated with PDGFR/Fc transfection were
plasma half-life [22]. In addition, the phenomenon of pro-significantly reduced compared with untreated disease
tein deposition in the glomerulus is well known. Largecontrols (Fig. 9). The level of GAPDH mRNA remained
particles may enter the mesangium through fenetratedunaffected in all transfected kidneys.
endothelium and mesangial pathway [45]. It remains un-
clear why the large size and anionic property of the
DISCUSSION molecule determines its mesangial localized deposition;
however, it may be feasible that a portion of the moleculeIn the present study, we demonstrated that PDGFR/Fc
gene transfer by electroporation to muscle ameliorated enables the specific delivery to the mesangium through
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this pathway. With this concept to deliver specific mole- [11] and that TGF-b, in turn, induces mesangial cells to
produce a variety of ECM components [43]. These re-cule into the glomerulus via gene transfer to muscle,
we have already shown that the chimeric TGFbRII/Fc sults suggest that PDGFR/Fc transfection may affect the
production of TGF-b within the glomeruli and might at-molecule was detected in the mesangial area, indicating
that TGFbRII/Fc was produced in the muscle and deliv- tenuate the matrix production with a concomitant effect
of TGF-b inhibition. However, on day 7, the suppressionered to the kidney [46]. Secreted chimeric PDGFR/Fc
was expected to be accumulated to the glomerular mes- of TGF-b1 and type I collagen expression in PDGFR/Fc-
treated nephritic muscle was not so drastic. Our observa-angial area of kidneys via the bloodstream as well.
In the Thy-1 model of glomerulonephritis, the mesan- tion that there was only partial suppression of extracellu-
lar matrix accumulation suggests that PDGFR/Fc couldgial cell population, which is almost completely elimi-
nated in the state of mesangiolysis, undergoes a rebound not block the vicious circle of TGF-b’s autocrine induc-
tion. Thus, a combination therapy targeting both PDGFproliferation that is accompanied by a marked up-regula-
tion of glomerular PDGF-B chain mRNA from day 2 to and TGF-b may be an ideal strategy.
It was reported that treatment with a twice-daily injec-day 4 after disease induction. It is reported that expressed
and secreted molecules from the transfected muscle could tion of PDGF-B aptamer from days 3 through 9 after
disease induction resulted in an inhibition of the over-be detectable in the glomeruli three days after transfec-
tion (2 days after disease induction) [8, 41]. Therefore, shooting mesangial cell proliferation, which led to a
marked reduction of glomerular hypercellularity [12].it is suggested that delivered PDGFR/Fc molecule could
counteract the overexpressed PDGF-BB in glomeruli. The possibility of developing aptamer antagonists for
defined biological mediators has become an attractiveIn the anti–Thy-1 model, mesangial cells proliferate
and undergo a transient phenotypic change to “myofi- novel therapeutic approach in various diseases; however,
gene therapy has several important advantages overbroblasts,” which express a-SMA [2, 47]. There is accu-
mulating evidence that the activated mesangial cell de- treatments with recombinant protein, aptamer, or oligo-
nucleotide. It does not require repeated intravascularvelops myofibroblast-like features in glomerular injury.
The cells expressing the a-SMA were located in mesan- injections for administration, and this alone may improve
compliance significantly. Sustained production and se-gial regions and were also actively proliferating. The
de novo expression of a-SMA may be required for the cretion of the protein by muscle cells may lead to contin-
uously retained concentrations and a greater therapeuticmesangial cell contractility and cell migration, which are
associated with matrix expansion and subsequent remod- effect than if administered by intravascular injection.
Recently, it was demonstrated that electroporation-eling within glomeruli. The fibroblast-like characteristics
of the activated mesangial cell are manifested by the mediated erythropoietin gene transfer into muscle re-
sulted in a continuous increase of serum erythropoietinproduction of interstitial collagens, in addition to the
normal mesangial matrix proteins. PDGF and a-SMA levels and increased erythropoiesis [48]. In addition, we
treated muscle with bupivacaine three days before trans-are selectively up-regulated in activated mesangial cells
in the anti–Thy-1.1 model [6, 47]. We demonstrated that fection. It was reported that bupivacaine treatment in-
duced regeneration of skeletal muscle and that in vivothe glomerular de novo expression of a-SMA was sig-
nificantly inhibited by the chimeric gene transfer. These transfection into regenerating muscle led to high levels of
transgene expression [33]. Aihara and Miyazaki reportedobservations suggest that PDGFR/Fc chimeric gene
transfer might reduce the mesangial phenotypic changes that electroporation was equally efficient at transferring
genes to mouse regenerating and normal muscle [28]. Inthrough the inhibition of PDGF action.
Previous studies have demonstrated that in this model, rat muscle, DNA solution seemed to distribute more
diffusely in regenerating muscle than in normal muscle,mesangial cell proliferation is accompanied by later
expansion of several matrix proteins in the mesangium. and we employed a pair of tweezers type of electrodes,
not but a needle type of electrodes reported in mouseIn the present study, the disease control rats with anti–
Thy-1 glomerulonephritis also showed a diffuse increase muscle. We observed that electroporation-mediated
gene transfer combined with bupivacaine pretreatmentin glomerular matrix accumulation. In contrast, the glo-
meruli from rats transfected with PDGFR/Fc transfec- resulted in 35 times higher levels of luciferase activities
than those without pretreatment. These results suggesttion showed significantly less accumulation of ECM. The
reduction in matrix accumulation in the PDGFR/Fc- that electroporation-mediated gene transfer combined
with bupivacaine pretreatment induced a widely distrib-treated rats may result from the attenuation of mesangial
cell growth. Of interest is that the chimeric PDGFR/Fc uted gene expression in rat regenerating muscle. Finally,
and importantly, gene therapy is advantageous becausetreatment reduced the increase in the TGF-b1 mRNA
level. Type I collagen expression was markedly sup- it is less expensive and overcomes the need to manufac-
ture and purify a recombinant protein.pressed on day 5. These findings support the findings
that PDGF induces mesangial cells to express TGF-b It has been suggested that the up-regulation of growth
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derived growth factor gene into the rat kidney. J Clin Investfactors and cytokines, such as PDGF and TGF-b, is in-
92:2597–2601, 1993
volved in the progression of glomerular diseases. There- 9. Leveen P, Pekny M, Gebre-Medhin S, et al: Mice deficient for
fore, adequate treatment for renal fibrosis may require PDGF B show renal, cardiovascular, and hematological abnormali-
ties. Genes Dev 8:1875–1887, 1994a multipharmacologic approach. These growth factors
10. Soriano P: Abnormal kidney development and hematological dis-and cytokine pathways participate individually to repair orders in PDGFb-receptor mutant mice. Genes Dev 8:1887–1896,
and restore cell/tissue function; however, these different 1994
11. Johnson RJ, Raines EW, Floege J, et al: Inhibition of mesangialpathways reinforce each other to push the repair process
cell proliferation and matrix expansion in glomerulonephritis ininto an excessive pathologic state. We previously showed the rat by antibody to platelet-derived growth factor. J Exp Med
that TGFbRII/Fc gene transfer had a therapeutic effect 175:1413–1416, 1992
12. Floege J, Ostendorf T, Janssen U, et al: Novel approach toon a later phase of glomerular injury and that PDGFR/Fc
specific growth factor inhibition in vivo antagonism of platelet-gene transfer had a therapeutic effect in an early phase derived growth factor in glomerulonephritis by aptamers. Am J
[46]. Incapacitating one or more pathways of growth Pathol 154:169–179, 1999
13. Claesson WL, Eriksson A, Moren A, et al: cDNA cloning andfactors and cytokines by gene transfer may tilt the bal-
expression of a human platelet-derived growth factor (PDGF)ance of forces to allow normal cell and tissue repair.
receptor specific for B-chain-containing PDGF molecules. Mol Cell
In conclusion, our study demonstrates a chimeric mol- Biol 8:3476–3486, 1988
14. Escobedo JA, Navankasatussas S, Cousens LS, et al: A commonecule designed to specifically inhibit the PDGF-mediated
PDGF receptor is activated by homodimeric A and B forms ofearly phase of glomerular injury and also to decrease
PDGF. Science 240:1532–1534, 1988
the later ECM accumulation. Notably, the chimeric mol- 15. Gronwald RG, Grant FJ, Haldeman BA, et al: Cloning and
expression of a cDNA coding for the human platelet-derivedecule was delivered to kidney from skeletal muscle,
growth factor receptor: Evidence for more than one receptor class.where the naked plasmid was transferred by electropora-
Proc Natl Acad Sci USA 85:3435–3439, 1988
tion. These results suggest that electroporation-mediated 16. Matsui T, Heidaran M, Miki T, et al: Isolation of a novel receptor
gene therapy by PDGFR/Fc may prove to be clinically cDNA establishes the existence of two PDGF receptor genes.
Science 243:800–804, 1989useful, given that the blocking of PDGF overexpression
17. Claesson WL, Eriksson A, Westermark B, Heldin CH: cDNAin the glomeruli provides a potentially powerful thera- cloning and expression of the human A-type platelet-derived
peutic approach to the treatment of PDGF-mediated growth factor (PDGF) receptor establishes structural similarity to
the B-type PDGF receptor. Proc Natl Acad Sci USA 86:4917–4921,glomerular diseases.
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